Cash, cash equivalents and short-term investments were $185.6M as of December 31, 2022, compared to $203.3M as of September 30, 2022, and $305.2M as of December 31, 2021. Adverum expects cash, cash equivalents and short-term investments to fund operations into 2025.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ADVM:
- Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
- Adverum Biotechnologies initiated with a Buy at Ladenburg
- Adverum Biotechnologies to Present at Upcoming Investor Conferences
Questions or Comments about the article? Write to editor@tipranks.com